Home / Healthcare/ AbbVie looks beyond Humira with $ 63 billion deal for Botox-maker Allergan

AbbVie looks beyond Humira with $ 63 billion deal for Botox-maker Allergan


Comments / {{hitsCtrl.values.hits}} Views / Wednesday, 3 July 2019 00:00


 


  • The world’s top-selling drug brought in sales of $ 20 billion last year

Reuters: Drugmaker AbbVie Inc. said on Tuesday it would acquire Allergan Plc for about $ 63 billion, giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses US patent protection.

AbbVie has long been under pressure to diversify its portfolio and its shares have lost more than a third of their value since January 2018 over concerns about Humira.

The world’s top-selling drug brought in sales of $ 20 billion last year. But it now faces competition from cheaper versions in Europe and a 2023 expiration of its patents in the United States, by far the most profitable market.

AbbVie Chief Executive Richard Gonzalez said the company was able to buy Allergan because of the massive amount of cash that Humira generates. A US corporate tax overhaul under the Trump administration, which helped companies bring back revenue earned overseas, also helped, he said.

“Humira is buying the assets that replace it over the long term,” said Gonzalez, who plans to lead the combined company and remain chairman and CEO through 2023.

Chief among those assets is Allergan’s Botox, a purified form of botulinum toxin that paralyzes muscles, smoothing frown lines and wrinkles in the forehead and around the eyes. The injection is also approved to treat chronic migraine headaches, overactive bladder and other medical uses.Botox had 2018 sales of about $ 3.6 billion, with $ 1.55 billion coming from cosmetic uses. When used as a cosmetic treatment, patients must pay for Botox out of pocket, buffering it from the pricing pressure that health insurers and government health agencies have put on prescription medicines.

AbbVie sees particular opportunity in the aesthetics market, which Gonzalez described as “highly underpenetrated” and primed to double by 2025, driven by increasing use by younger consumers looking to head off wrinkles before they start.

In addition, Gonzalez said he does not expect a biosimilar version of Botox “for a long, long time, if ever.”Both therapeutic and cosmetic Botox are expected to keep growing, with analysts forecasting total 2019 sales of $ 3.9 billion and reaching nearly $ 6 billion by 2025, according to Refinitiv data.

“We believe the increasing concern about AbbVie’s growth potential following the US Humira biosimilar competition in 2023 will be partially alleviated with the increased portfolio of assets that Allergan brings,” said Morningstar analyst Damien Conover.The deal, coming months after Bristol-Myers Squibb Co agreed to buy Celgene Corp for $ 74 billion, also highlights renewed interest in major acquisitions by the pharmaceutical industry.

 


Share This Article

Facebook Twitter


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

Ministry of Civil Aviation: A nation rich in connectivity

Wednesday, 23 October 2019

lIncrease runway movement from 11 to 17 departures per hour at BIA. lFacilitate an optimum structure to ensure a strong network of airports.


Elpitiya test market: Implications for brands Gota and Sajith

Wednesday, 23 October 2019

In the traditional world of marketing, we tend to test market a product before going national with it. There are three test marketing areas that are normally selected by FMCG companies - Gampaha, Kandy and Negombo. The logic behind this is that the c


How to promote innovations to transform our nation

Wednesday, 23 October 2019

“There is only one thing stronger than all other armies of the world: and that is an idea whose time has come” – Victor Hugo A country’s economic success and prosperity largely depends on the technological advancement it embraces and the leve


An efficient energy sector for economic growth

Tuesday, 22 October 2019

When I saw the advertisement about an Energy Forum organised by PUCSL for a Policy Dialogue on the importance of an efficient energy sector for economic and investment growth, I was very happy as I have been interested in this relationship for more t


Columnists More